Literature DB >> 8575486

Efficient one-step direct labelling of recombinant antibodies with technetium-99m.

M Liberatore1, D Neri, G Neri, A Pini, A P Iurilli, F Ponzo, G Spampinato, F Padula, A Pala, A C Colella.   

Abstract

High-affinity bacterially expressed antibody fragments can nowadays be cloned from established hybridomas or, more conveniently, isolated directly from antibody libraries displayed on filamentous phage. Such antibodies can be tagged with C-terminal peptide tags containing one cysteine residue, which represents a convenient functionalisation site for a number of applications, including technetium-99m labelling. Here we describe a simple one-step method for 99mTc labelling of cysteine-tagged recombinant antibodies with more than 50% radionuclide incorporation. The labelled antibodies displayed full retention of immuoreactivity and good stability.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8575486     DOI： 10.1007/bf00801622

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN： 0340-6997


  12 in total

1.  Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains.

Authors:  H R Hoogenboom; A D Griffiths; K S Johnson; D J Chiswell; P Hudson; G Winter
Journal:  Nucleic Acids Res       Date:  1991-08-11       Impact factor: 16.971

Review 2.  Engineering recombinant antibodies for immunotherapy.

Authors:  D Neri; H Petrul; G Roncucci
Journal:  Cell Biophys       Date:  1995-08

3.  In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity.

Authors:  C F Barbas; D Hu; N Dunlop; L Sawyer; D Cababa; R M Hendry; P L Nara; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

Review 4.  Making antibodies by phage display technology.

Authors:  G Winter; A D Griffiths; R E Hawkins; H R Hoogenboom
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

5.  Comparative stabilities in vitro and in vivo of a recombinant mouse antibody FvCys fragment and a bisFvCys conjugate.

Authors:  A J Cumber; E S Ward; G Winter; G D Parnell; E J Wawrzynczak
Journal:  J Immunol       Date:  1992-07-01       Impact factor: 5.422

6.  A single chain Fv derived from a filamentous phage library has distinct tumor targeting advantages over one derived from a hybridoma.

Authors:  M J Verhaar; K A Chester; P A Keep; L Robson; R B Pedley; J A Boden; R E Hawkins; R H Begent
Journal:  Int J Cancer       Date:  1995-05-16       Impact factor: 7.396

7.  Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli.

Authors:  P Pack; M Kujau; V Schroeckh; U Knüpfer; R Wenderoth; D Riesenberg; A Plückthun
Journal:  Biotechnology (N Y)       Date:  1993-11

8.  By-passing immunization: building high affinity human antibodies by chain shuffling.

Authors:  J D Marks; A D Griffiths; M Malmqvist; T P Clackson; J M Bye; G Winter
Journal:  Biotechnology (N Y)       Date:  1992-07

9.  Improved tumor targeting with chemically cross-linked recombinant antibody fragments.

Authors:  D J King; A Turner; A P Farnsworth; J R Adair; R J Owens; R B Pedley; D Baldock; K A Proudfoot; A D Lawson; N R Beeley
Journal:  Cancer Res       Date:  1994-12-01       Impact factor: 12.701

10.  Isolation of high affinity human antibodies directly from large synthetic repertoires.

Authors:  A D Griffiths; S C Williams; O Hartley; I M Tomlinson; P Waterhouse; W L Crosby; R E Kontermann; P T Jones; N M Low; T J Allison
Journal:  EMBO J       Date:  1994-07-15       Impact factor: 11.598
View more
  1 in total

1.  Antigen specificity and tumour targeting efficiency of a human carcinoembryonic antigen-specific scFv and affinity-matured derivatives.

Authors:  H Jackson; L Bacon; R B Pedley; E Derbyshire; A Field; J Osbourn; D Allen
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.